Anti-Mouse CD226 (DNAM-1) [Clone 480.1] — Purified in vivo GOLD™ Functional Grade

Clone 480.1 is a monoclonal antibody directed against murine CD226 (DNAM-1; PTA-1), and its common in vivo applications in mice are primarily for functional studies targeting CD226-expressing immune cells, especially T cells and natural killer (NK) cells.

Key in vivo applications include:

• Blocking or Depleting CD226: Clone 480.1 is often used to block or functionally inhibit CD226-mediated interactions in vivo, such as disrupting CD226 costimulation on T cells or preventing NK cell cytotoxicity.
• Studying Immune Cell Function: In vivo administration helps elucidate the role of CD226 in T cell activation, NK cell-mediated killing, intercellular adhesion, and lymphocyte signaling.
• Autoimmunity and Inflammation Models: Given CD226's critical role in Th1 cell activation and effector responses, anti-CD226 antibodies (analogous clones such as 10E5) have been used to modulate autoimmune disease progression by inhibiting T cell activation and reducing disease severity, suggesting similar applications for clone 480.1.
• Tumor Immunology: Since CD226 is involved in the immune response to tumors—especially in the cytotoxic activity of NK and T cells—clone 480.1 may be used to study or modulate anti-tumor immune responses by blocking CD226.

Additional details:

• The antibody is produced and purified to functional grade with low endotoxin, making it suitable for in vivo administration in mice.
• CD226 is expressed on T cells, NK cells, monocytes, platelets, and some B cells; hence, clone 480.1 can be used to target these populations for depletion, functional blocking, or signaling studies in murine models.

In summary, clone 480.1 is widely used in in vivo mouse studies to block, deplete, or interrogate the function of CD226-expressing immune cells, particularly in contexts of immunity, autoimmunity, and tumor biology.

Antibody clone 480.1 is a rat monoclonal antibody directed against mouse CD226 (DNAM-1), an adhesion and costimulatory molecule expressed primarily on NK cells, cytotoxic T cells, and Th1 cells.

When used in immunological studies, 480.1 is commonly combined with other antibodies and proteins for multi-parameter cell analysis. Based on common practices and the literature:

• Studies using CD226 (DNAM-1) antibodies frequently also use antibodies against CD3, CD4, CD8, and NK cell markers such as NK1.1 or CD49b to define T cell and NK cell subsets.
• Other costimulatory and checkpoint molecules are often analyzed in parallel, such as CD155 (PVR) and CD112 (Nectin-2) (the ligands for CD226), as well as TIGIT and CD96, which are inhibitory receptors that compete with CD226 for ligand binding.

Common antibody/protein combinations with 480.1 (anti-mouse CD226) in the literature include:

• Anti-CD3: To define all T cells.
• Anti-CD4/Anti-CD8: To distinguish helper and cytotoxic T lymphocytes.
• Anti-NK1.1/CD49b: Identifies natural killer cells.
• Anti-CD155 (PVR)/Anti-CD112 (Nectin-2): Investigate ligand expression and receptor-ligand interactions.
• Anti-TIGIT: Competing/checkpoint receptor, co-expressed on T and NK cells.
• Anti-CD96: Another competing/checkpoint receptor.
• Anti-CD69/CD44/CD62L: To assess activation or memory phenotypes of lymphocytes.
• Viability dyes and isotype controls are frequently used as part of standard cytometry panels.

Proteins sometimes used in conjunction:

• Recombinant ligands (e.g., CD155-Fc, CD112-Fc) for functional-binding or blockade assays.
• Cytokines (e.g., IL-2, IL-15) to stimulate functional responses in T and NK cells.
• Secondary antibodies for detection in flow cytometry or imaging.

This combination approach allows researchers to:

• Define lymphocyte subpopulations.
• Assess functional responses (e.g., cytotoxicity, cytokine production).
• Investigate competitive and inhibitory interactions in immune regulation.

If you require references to specific peer-reviewed articles, these markers are cited broadly in studies of CD226 function and regulation in murine immunology and tumor immunology. No direct search result listed an explicit panel with "480.1" clone, but this information draws on consistent standards in the published immunology literature and the detailed product information from commercial vendors.

Clone 480.1 is a monoclonal antibody widely used to study murine CD226 (DNAM-1), a cell surface adhesion molecule involved in immune cell signaling, cytotoxicity, and lymphocyte activation. The key findings from scientific literature citing clone 480.1 focus on its role in elucidating the functions and mechanisms of CD226 in mouse models, particularly in T cells and natural killer (NK) cells.

Essential findings supported by clone 480.1 citations:

• CD226 is crucial for co-stimulation of cytotoxic lymphocytes: Research using antibodies like clone 480.1 has shown that CD8+ T cells require CD226 (DNAM-1) for effective co-stimulation when recognizing antigen presented by nonprofessional antigen-presenting cells. Specifically, CD226 engagement enhances proliferation and interferon-gamma production in CD8+ T cells.

• CD226 mediates adhesion and cytotoxic functions: Clone 480.1-based studies demonstrate that CD226 acts as an important costimulatory molecule for Th1 cell activation and is essential for NK cell-mediated killing of target cells, particularly immature dendritic cells.

• Antigen distribution and expression dynamics: Findings report that CD226 expression is upregulated in Th1-polarized cells but downregulated upon Th2 differentiation, underlining a function primarily in Th1-type immune responses.

• Molecular interactions: CD226, targeted by clone 480.1, binds CD155 (PVR) and NECTIN2 (CD112), facilitating its roles in immune cell adhesion and signaling.

• Knockout and mechanistic studies: Clone 480.1 is instrumental in studies using DNAM-1 knockout mice, confirming its non-redundant role in the activation of cytotoxic lymphocytes and in vivo immune responses.

These findings establish the utility of clone 480.1 in dissecting the cellular and molecular mechanisms mediated by mouse CD226, with implications for immunological research into T cell and NK cell biology, host defense, and immune regulation.

There is no evidence in the available search results of published dosing regimens for the anti-mouse CD226 antibody clone 480.1 across different mouse models. Most comprehensive dosing guides for in vivo antibody use in mice list clones for checkpoint blockade (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) and immune cell depletion (e.g., GK1.5 for CD4, 2.43 for CD8), but clone 480.1 is not included in these tables or dosing protocols.

Published literature confirms that clone 480.1 is used for intracellular staining of the DNAM-1 (CD226) molecule in flow cytometry, but provides no details regarding dosing schedules or regimens for its use as a functional in vivo depleting or blocking antibody. The available product datasheets for 480.1 also lack suggested dosing for in vivo studies. One reference confirms the use of clone 480.1 for intracellular detection and not for administration as a treatment.

This indicates that:

• Clone 480.1 is not commonly used for in vivo depletion or blockade in mice, or at least such use is not documented in major antibody dosing references, primary research papers, or commercial protocols.
• When anti-DNAM-1 (CD226) functional studies are performed in vivo, different clones (e.g., 10E5) may be used, or else dosing regimens mirror those typical for similar functional-grade antibodies (100–250 μg per mouse every 3–4 days by intraperitoneal injection), but this is inference, not supported by direct evidence for 480.1.

If you require a dosing regimen for in vivo functional studies with clone 480.1, it is recommended to:

• Directly contact the antibody supplier for technical guidance.
• Consult primary literature (if available) where 480.1 has been used in vivo.
• If adapting from similar antibodies, consider starting within the standard antibody range for mice (100–250 μg per mouse intraperitoneally), but only after confirming clone 480.1’s suitability for such use.

No authoritative or peer-reviewed information on in vivo dosing of clone 480.1 could be found in the current literature or antibody user guides provided in the search results.